11:58 AM EST, 11/11/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) third-quarter results were solid across the board, with revenue up 31.7% to $121.5 million and adj. EBITDA of $21 million particularly strong, demonstrating the so-far successful re-integration of Paladin with Knight's core business, notes Stifel Canada.

The topline was further supported by the addition of the recently acquired Sumitomo portfolio (Canadian rights to Myfembree, Orgovyx and vibegron). The strong print resulted in an upward F2025 guidance revision to $430 million - $440 million in revenue (from $410 million to $420 million) and 13.5-14.5 adj. EBITDA margin (from 13%).

The revised guidance gives Stifel analyst Justin Keywood in a "new better-than anticipated baseline for go-forward revenues under the combined enterprise." Execution of favorable guidance should help re-rate shares with M&A serving as catalysts, he adds.

Knight Therapeutics ( KHTRF ) is rated Buy, with a $7.45 target.

Price: 6.09, Change: +0.04, Percent Change: +0.66